Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes

08-Nov-2023 - Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven ...

Evotec announces agreement with Janssen to develop immune-based therapies

Strategic partnership in oncology

26-Jan-2023 - Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for ...

Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas

24-Sep-2019 - Evotec SE announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Under the collaboration, the parties aim to establish at least five drug discovery programmes with the goal of Evotec delivering clinical candidates for Takeda to pursue into ...

Evotec and The Mark Foundation for Cancer Research announce strategic collaboration in immuno-oncology

27-Mar-2019 - Evotec AG and The Mark Foundation for Cancer Research today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery ...

Evotec and Celgene enter into strategic oncology partnership

22-May-2018 - Evotec AG announced that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Evotec has built one of the industry's broadest and most innovative pre-clinical discovery and development ...

Evotec forms collaboration with Petra Pharma on INDiGO platform

12-Apr-2018 - Evotec AG announced a strategic collaboration with Petra Pharma Corporation. Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the ...

Evotec Receives Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

22-Aug-2011 - Evotec AG announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec. The milestone was achieved for the identification and selection of a compound to be advanced into pre-clinical development within an oncology ...

Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim

21-Jun-2010 - Evotec AG announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme. Dr Werner ...

Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim

Evotec receives EUR 2.0 million milestone payment from Boehringer Ingelheim

20-May-2010 - Evotec AG announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million. The compound, which was discovered and ...